Turkish Journal of Medical Sciences
Volume 51

Number 3

Article 4

1-1-2021

Treatment of SARS-CoV-2 pneumonia with favipiravir: early results
from the EgeUniversity cohort, Turkey
HÜSEYİN AYTAÇ ERDEM
PERVİN KORKMAZ EKREN
DERYA ÇAĞLAYAN
MELTEM TAŞBAKAN
TANSU YAMAZHAN

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ERDEM, HÜSEYİN AYTAÇ; EKREN, PERVİN KORKMAZ; ÇAĞLAYAN, DERYA; TAŞBAKAN, MELTEM;
YAMAZHAN, TANSU; TAŞBAKAN, MEHMET SEZAİ; SAYINER, ABDULLAH; and GÖKENGİN, AYŞE DENİZ
(2021) "Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the EgeUniversity cohort,
Turkey," Turkish Journal of Medical Sciences: Vol. 51: No. 3, Article 4. https://doi.org/10.3906/
sag-2008-33
Available at: https://journals.tubitak.gov.tr/medical/vol51/iss3/4

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the
EgeUniversity cohort, Turkey
Authors
HÜSEYİN AYTAÇ ERDEM, PERVİN KORKMAZ EKREN, DERYA ÇAĞLAYAN, MELTEM TAŞBAKAN, TANSU
YAMAZHAN, MEHMET SEZAİ TAŞBAKAN, ABDULLAH SAYINER, and AYŞE DENİZ GÖKENGİN

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol51/iss3/4

Turkish Journal of Medical Sciences

Turk J Med Sci
(2021) 51: 912-920
© TÜBİTAK
doi:10.3906/sag-2008-33

http://journals.tubitak.gov.tr/medical/

Research Article

Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege
University cohort, Turkey
1,

2

1

1

Hüseyin Aytaç ERDEM *, Pervin KORKMAZ EKREN , Derya ÇAĞLAYAN , Meltem IŞIKGÖZ TAŞBAKAN ,
1
2
2
1
Tansu YAMAZHAN , Mehmet Sezai TAŞBAKAN , Abdullah SAYINER , Deniz GÖKENGİN 
1
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, İzmir, Turkey
2
Department of Chest Diseases, Faculty of Medicine, Ege University, İzmir, Turkey
Received: 05.08.2020

Accepted/Published Online: 24.11.2020

Final Version: 28.06.2021

Background/aim: The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment
of severe SARS-CoV-2 pneumonia.
Materials and methods: This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or
developed severe pneumonia.
Results: Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%)
patients required treatment for respiratory distress. Thirty-three patients (82.5%) were discharged from the hospital with full recovery,
6 patients (15%) died and 1 case (2.5%) was still at the intensive care unit (ICU) when this paper was written.
Conclusion: This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with
significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would
merit further investigation.
Key words: SARS-CoV-2, favipiravir, COVID-19, coronavirus, pandemic, antiviral therapy

1. Introduction
The large-scale pandemic due to the severe acute
respiratory syndrome coronavirus (SARS-CoV-2), which
started in November 2019 in Wuhan, China has caused
4,425,485 confirmed cases of coronavirus infectious
disease (COVID-19) in 216 countries, and 302,059
confirmed deaths as of May 16th, 2020.1
SARS-CoV-2 is reported to be transmitted from human
to human by droplets and to cause lower respiratory tract
infection, which may result in severe respiratory distress
and death [1]. Treatment of COVID-19 is challenging
as there is no proven treatment strategy yet. Small-scale,
randomized controlled trials and observational cohort
studies are available for several drugs with controversial
results. Chloroquine/hydroxychloroquine, azithromycine,
lopinavir/ritonavir, favipiravir, and remdesivir, are some of
which have been shown to have in vitro activity against
MERS-CoV, SARS-CoV, other coronaviruses and various
other viruses. These drugs are among those that are most

promising, but with controversial results in clinical studies
that are difficult to interpret [2–17].
While it is difficult to design a treatment approach
without proven benefit of a drug or a treatment regimen,
the severity of the situation calls for urgent action.
Considering the emergency state we are all in, every
piece of data counts and contributes to the knowledge
and understanding of the pandemic, helping us shape our
approach to treating the patients. The aim of this descriptive
article is to share the experience in Ege University, Turkey
with favipiravir in the treatment of severe SARS CoV-2
pneumonia by providing real-world data while waiting for
the solid evidence to build up.
2. Materials and methods
This retrospective descriptive study included patients
diagnosed with COVID-19 who were hospitalized in
the Department of Clinical Microbiology and Infectious
Diseases and the Department of Chest Diseases, at Ege

Republic of Turkey Ministry of Health (2020). Guidelines for the Management of Adults with COVID-19 [online]. Website https://covid19bilgi.saglik.
gov.tr/depo/rehberler/COVID-19_Rehberi.pdf [accessed 01 May 2020].
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University Faculty of Medicine from March 23rd to April
26th 2020. The diagnosis was made by a positive nucleic
acid amplification test (NAAT) from nasopharyngeal
swabs (Coyote Biosciences, San Jose, CA, USA) and
radiologic findings in line with COVID-19 pneumonia
[19]. Patients who presented with or developed severe
pneumonia [tachypnea (> 30 breaths/min) and/or hypoxia
(SpO2 < 90% on room air) and/or bilateral diffuse ground
glass infiltrations] with no response to first-line treatment
with HCQ (± azithromycin) and started favipiravir were
included.
The treatment approach was in line with the
recommendations of the Guidelines for the Management
of Adults with COVID-19 produced by the Turkish
Ministry of Health.1
Favipiravir 200 mg tablets were administered orally
starting with a loading dose of 1600 mg bid, followed by
600 mg bid daily for 5 to 7 days.
For each patient, demographic characteristics,
underlying conditions, clinical signs and symptoms,
radiologic and laboratory findings, oxygen requirement,
and adjunctive treatments used were recorded. Response
to favipiravir treatment was assessed by comparison of
baseline and day 4 of treatment in terms of the level of
respiratory distress and laboratory parameters [white
blood cell count and differential, lactate dehydrogenase
(LDH), C-reactive protein (CRP), ferritin, fibrinogen,
d-dimer, and procalcitonin].
Oxygen therapy was classified as oxygen delivery via
face mask, continuous positive airway pressure (CPAP)
and invasive mechanical ventilation (IMV). Respiratory
distress level and chest X-ray/high resolution computed
tomography (HRCT) findings were evaluated at baseline
prior to initiation of favipiravir and on day 4 of the
treatment. Patients who did not require oxygen therapy
before or after favipiravir treatment were defined as the
“ambient air” group. Patients whose oxygen requirement
did not change from baseline until day 4 were classified
as the “no change” group. Patients whose oxygen
requirement reduced from baseline to day 4 were grouped
as “improvement”, and those whose oxygen requirement
increased were defined as “impairment”. Treatment was
considered successful for patients who were discharged
from the hospital with no symptoms, improvement in
chest radiology, and no respiratory distress. In addition,
adverse events and serious adverse events that developed
during favipiravir treatment were recorded.
2.1. Statistical analysis
Data was analyzed using SPSS v.18.0 (SPSS Inc.,
Chicago, IL, USA). Numbers and percentages were
used for categorical variables. Mean values with
standard deviations, and median values with minimum
and maximum values were calculated for continuous

variables. Continuous variables were tested for agreement
with normal distribution. Since all variables did not
show normal distribution in graphical analyses and
normalization tests, and considering the size of the study
population, nonparametric methods were preferred for
comparisons. The Wilcoxon signed ranks test was used to
analyze the change in repeating measurements. A type-1
error α was determined as 0.05 and was tested. A value
of p < 0.05 was considered statistically significant and was
represented with a box pilot graphic.
3. Results
Out of a total of 559 patients admitted to the hospital, 40
patients who completed a full course (at least 5 days) of the
drug during the study period were included in the study.
More than half (58%) of the patients were male. The mean
age was 55.58 ± 13.49 (26–79 years). All patients were
confirmed COVID-19 cases with positive nasopharyngeal
swabs. Two thirds of the patients had at least one underlying
disease, and the most common underlying conditions were
cardiovascular disease and diabetes mellitus. The most
common clinical symptoms were fever and cough; almost
all (95%) patients had more than one symptom. Baseline
demographic characteristics, comorbidities, clinical signs
and symptoms, as well as respiratory distress levels are
shown in Table 1.
Twenty (50%) patients were managed in the intensive
care unit (ICU); 5 patients were admitted directly to the
ICU at presentation and 15 patients were transferred to
the ICU from the clinic ward due to clinical worsening.
The mean duration of stay at the ICU was 9.31 (1–19)
days. At baseline, 30 (75%) patients required treatment
for respiratory distress, Table1. While 9 patients (22.5%)
maintained respiration at ambient air before and after
favipiravir treatment, oxygen requirement increased in
13 (32.5%) patients, decreased in 12 (30%) and did not
change in 6 (face mask/nasal cannula, CPAP or IMV)
(15%) on day 4 of favipiravir treatment. The change in
oxygen requirement after favipiravir treatment did not
differ according to age or sex (p > 0.05). On day 4 of
favipiravir treatment, radiologic findings improved or did
not deteriorate in 42.5% of the cases, and deteriorated in
42.5%; no radiologic follow-up was available in 15%.
Table 2 includes laboratory findings before and 24 h
after the termination of favipiravir treatment. C-reactive
protein, procalcitonin, LDH and d-dimer levels were
elevated before favipiravir treatment; while CRP,
procalcitonin and LDH levels decreased significantly,
d-dimer levels continued to increase after favipiravir
treatment. Figure 1 shows the distribution of statistically
significant laboratory results.
Adverse events developed in 5 patients (13%) during
favipiravir treatment. All five had mild to moderate
elevations in hepatic enzymes. Three of these cases also

913

ERDEM et al. / Turk J Med Sci
Table 1. Demographic and baseline (prior to initiation of
favipiravir) characteristics of patients.
Characteristics

n = 40 (%)

Age groups
≤50 year

12 (30)

50 to < 70 year

22 (55)

≥70 year

6 (15)

Sex
Male

23 (58)

Female

17 (42)

Health care workers

6 (15)

Underlying medical conditions

25 (63) (at least one)

Hypertension

12 (30)

Diabetes mellitus

11 (28)

Coronary artery disease

5 (13)

Malignancy

3 (8)

Hypothyroidism

3 (8)

Asthma

2 (5)

Contact with confirmed
COVID-19 infection

17 (43)

Signs and symptoms
Fever

34 (85)

Cough

29 (73)

Dyspnoea

15 (38)

Sore throat

11 (28)

Fatigue

10 (25)

Sputum production

7 (18)

Diarrhea

7 (18)

Oxygen support status at baseline
Face mask

19 (47.5)

Ambient air

10 (25)

CPAP

7 (17.5)

Mechanical ventilation

4 (10)

Need for inotropes or vasopressors
during favipiravir treatment

4 (10)

reported nausea and one case developed neutropenia.
Adverse events were resolved spontaneously, no patient
developed a serious adverse event and no patient
discontinued favipiravir due to adverse events. While 17
patients required no adjunctive treatment, 23 patients
received various combinations of favipiravir with
tocilizumab, corticosteroid, intravenous immunoglobulin
(IVIG), and plasma transfer. Low molecular weight
heparin (LMWH) was administered to 34 patients (85%).
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Thirty-three patients (82.5%) were discharged from
the hospital with full recovery, 6 patients (15%) died and
1 case (2.5%) was still at the ICU when this paper was
written. Of those who died, 4 were older than 65 years
and the remaining two were 52 and 64 years old. All
patients who died had started favipiravir when they were
already in the ICU, had at least one serious comorbidity
excluding one 64-year old case, and had received various
combinations of tocilizumab (n = 5), corticosteroid (n
= 5), and plasma transfer (n = 1). Figure 2 summarizes
the method of treatment for respiratory distress before
and after favipiravir treatment, and the outcome of each
patient.
Overall 30/40 patients were screened with
nasopharyngeal swabs after the completion of favipiravir
treatment before or after discharge at different time points.
Twenty-seven patients were negative. Of the remaining
3 patients with positive results, 1 recovered and was
discharged from the hospital without a negative result, 2
died before a negative result.
4. Discussion
This study is the first from Turkey and one of the few
globally on favipiravir use in the treatment of COVID-19
patients with severe pneumonia. Despite its retrospective
nature, it may aid in providing insight into whether
favipiravir deserves further investigation and may be an
option for treating COVID-19 patients by presenting real
world data.
COVID-19, an acute respiratory condition due to SARSCoV-2 has spread rapidly resulting in a pandemic with
devastating effects within a few months since November
2019. Unlike its predecessor SARS, asymptomatic cases are
present, the viral load peaks earlier and commonly before
the patient is symptomatic, transmission rate is higher, and
attack rates are variable in different geographic regions
in SARS-CoV-2 infection, which makes containment
difficult and creates an emergency for rapid action [18–23].
Although more than 80% of the patients with COVID-19
have mild pneumonia, which usually resolves rapidly,
13%–18% of the cases develop severe pneumonia and 4%–
9% are reported to be critically ill [23,24]. Individuals with
diabetes and hypertension were reported to have a higher
likelihood of developing severe infection (44.5% and
41.7%, respectively) and a higher case fatality rate [23,24].
The analysis of our cohort including severe COVID-19
cases revealed a relatively high age distribution and a high
rate of comorbidities with hypertension and diabetes being
the most common, in line with the results of other cohorts
[25,26]. The outcome of severe COVID-19 is poor, mostly
requiring hospitalization at the ICU and mechanical
ventilation [26].
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Table 2. Laboratory findings of patients with COVID-19.
Initiation of favipravir
median (min-max)

End of favipravir
median (min-max)

p value

Leukocyte (cell/mm3) (n = 37)

6070 (3320–20770)

6690 (3830–17130)

0.23

Neutrophil (cell/mm ) (n = 37)

4710 (1880–19570)

4600 (1790–15960)

0.47

Lymphocytes (cell/mm3) (n = 37)

890 (290–2410)

1310 (390–3470)

0.001

C-reactive protein (mg/L) (n = 37)

104 (9–327)

24 (1–311)

<0.001

Procalcitonin (mg/L) (n = 24)

0.24 (0.02–2.18)

0.15 (0.02–0.71)

0.003

Ferritin (µg/L) (n = 24)

696 (86–3498)

565 (103–4188)

0.97

D-dimer (mg/L) (n = 32)

938 (377–4472)

1426 (527–4473)

0.001

Lactate dehydrogenase (U/L) (n = 26)

355 (149–835)

261 (144–714)

0.001

Alanine aminotransferase (U/L) (n = 38)

29 (5–258)

46 (6–198)

0.001

Aspartate aminotransferase ( U/L) (n = 38)

41 (6–269)

32 (9–149)

0.41

Laboratory results

3

A major challenge in the COVID-19 pandemic is the
lack of evidence on reliable treatment options. Although
various agents are under investigation in ongoing clinical
trials, the urgency of the situation has led scientists
to use empirical treatments or drugs that have been
investigated for other viruses in the past. Chloroquine
and its derivative HQ, which are antimalarial drugs were
among the most studied and recommended molecules
for the treatment of COVID-19 based on earlier reports
on their in vitro antiviral effects on SARS virus [27]
and their antiinflammatory and immunomodulator
effects [5]. Several clinical studies were undertaken to
study the clinical success of CQ/HQ as monotherapy
or coadministered with azithromycine with conflicting
results [13,14,17,28]. A metaanalysis showed that although
HCQ treatment compared to standard treatment had some
clinical benefits, there was no difference in virologic cure,
clinical progression or death rates [28].
Similarly, clinical studies reported controversial results
with LPV/r [16,29,30]. A systematic review reported that
no specific conclusion could be drawn for the efficacy of
LPV/r in COVID-19 [31].
Favipiravir was shown to inhibit a wide array of RNA
viruses such as the influenza virus, arenavirus, bunyavirus,
flavivirus, and filoviruses [32] and to improve survival in
patients with Ebola virus infection [33,34]. It was considered
as a potential candidate for the treatment of COVID-19
and the urgency of the situation required its premature
use without in vitro and animal studies [35]. Favipiravir
was studied in a few randomized controlled studies with
promising results. It was reported to significantly shorten
the time to viral clearance and alleviate the symptoms
of pneumonia, thereby improving the chest imaging
compared to LPV/r [36]. It also had a significantly higher
recovery rate compared to umifenovir, and shortened

the time with fever and respiratory symptoms even in
patients with hypertension and diabetes, albeit with no
statistically significant difference between the two drugs in
terms of requirement for oxygen support and noninvasive
mechanical ventilation [37].
Favipiravir did not become a favored drug globally
and was recommended and used only in Japan, China and
Turkey during the pandemic [38].1 Since the beginning of
the epidemic the Guidelines for the Management of Adults
with COVID-19 produced by the Turkish Ministry of
Health has suggested the addition of favipiravir or LPV/r
in COVID-19 patients who do not respond to first-line
treatment with HCQ and develop severe pneumonia, and
direct initiation of favipiravir or LPV/r ± HCQ to those that
present with severe pneumonia.1 Th treatment approach
in the Ege University was to initiate favipiravir in severe
cases after, during or in addition to HQ treatment. The
main reason to prefer favipiravir over LPV/r was previous
experience with LPV/r in people living with HIV in terms
of severe adverse events sometimes leading to permanent
discontinuation of the drug. Despite its retrospective design
the results of our study suggest a high rate of improvement
in severe COVID-19 patients. More than 80% of the
patients, including several who received noninvasive and
invasive mechanical ventilation were discharged from the
hospital with full recovery. The most notable finding was
an early response in approximately a third of the patients
in terms of reduced oxygen requirement with further
improvement within time. In addition, all cases but one that
required no oxygen support at baseline maintained their
status after favipiravir treatment. The favorable outcome
in the majority of the cases ()resulting with full recovery
was promising, although several patients recovered at later
stages. The poorest response was among those who were
already on IMV or CPAP when favipiravir was initiated
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Figure 1. Distribution of statistically significant laboratory results.

suggesting that early initiation of the drug before or
right after respiratory distress or radiologic deterioration
develops might be most beneficial. Favipiravir treatment
did not seem to have a major effect on the resolution of
radiologic findings at early stages in contrast to the findings
of Cai et al. This may be attributed to the severity of lung
involvement in our cases mostly requiring oxygen support
whereas those with severe pneumonia were excluded in
the study by Cai et al. [36].
Favipiravir proved to have a favorable safety profile
both for COVID-19 and influenza treatment at various
dosing regimens and compared to umifenovir and LPV/r,
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the most common adverse events being elevations in
liver enzymes and bilirubin as well as gastrointestinal
disturbances, and elevations in uric acid [36,37,39]. Our
cohort confirms the safety of the drug even in severe
pneumonia cases with multiple comorbidities using other
adjunctive therapies. There was no serious adverse event
that resulted with discontinuation of the drug.
The severity of the COVID-19 pneumonia is
associated with a cytokine storm with increased levels of
proinflammatory cytokines and ferritin causing severe
inflammation and hypoxia [40–42]. In addition, the
development of thromboembolic events worsens the

ERDEM et al. / Turk J Med Sci

Figure 2. Oxygen support status before and after favipiravir treatment, and outcomes of the patients.

situation, sometimes even leading to death. Elevated
d-dimer level was suggested to be an independent
risk factor for death [43]. Thus, adjunctive treatment
approaches in addition to antiviral treatment to alleviate
the inflammation such as anticytokinic biological agents,

corticosteroids and IVIG in addition to anticoagulants,
and especially LMWH were recommended [40,42,44]. The
antiinflammatory effects of CQ/HCQ and azithromycine
have also been suggested to contribute to the management
of inflammation [5]. The analysis of our patients reveal
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increased levels of inflammation markers, ferritin, and
d-dimer, which are in line with the severity of the condition.
Various adjunctive treatments were used to address
the inflammation and coagulopathy in our patients.
While inflammation markers reduced significantly after
the relevant treatment approach, high d-dimer levels
maintained despite the use of heparin and this may be
related to the course of the disease. Tang et al. reported
that elevated d-dimer levels were significantly associated
with higher mortality and although nonsignificant, 28day mortality was lower in heparin users compared to
nonusers. Timely and correct use of corticosteroids in
conjunction with ventilator support may be life-saving
in severe COVID-19 patients by preventing ARDS
[41,45,46]. It was not possible to analyze the association of
inflammation and coagulation markers to patient outcome
due to the small size of the study group.
This study has several limitations:
(1) This is not a randomized controlled study and its
level of evidence is low.
(2) The study group was too small to make detailed
statistical analyses.
(3) It was difficult to define the role of favipiravir in
the recovery of the patients because many additional
adjunctive treatments were administered.
(4) Patients were not followed-up for the duration of
time required for viral clearance.

However, despite these limitations, this study provides
relevant information for the treatment of COVID-19,
suggesting that favipiravir was associated with significant
clinical and laboratory improvements in the majority of
the patients and is a safe drug with no serious side effects.
Currently there are several completed and ongoing clinical
trials studying favipiravir [47] and in a time of emergency
when drugs found ineffective in randomized clinical trials
[48] are authorized for emergency use by drug agencies it
would merit further investigation.2,3
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